Floatz logo

Auto-Cd34+ Cells

Ischemic Disease

Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanCell therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Ischemic Disease cohort.

Asset / SponsorPhaseRating
Aspirin
Xijing Hospital
Phase 4BBB
Pregabalin
Karolinska Institutet
Phase 4BB
Urokinase-Type Plasminogen Activator
medac GmbH
Phase 3BB
Vorapaxar
Merck Sharp & Dohme LLC
Phase 3B
Tocilizumab
Zhujiang Hospital
Phase 3B

View all 9 →

Same molecule, other indications

Auto-Cd34+ Cells is also rated in:

coronary artery disorderDormant
BB
Indicative · Phase 3
66 / 100
View asset →
myocardial ischemiaDormant
BB
Indicative · Phase 3
66 / 100
View asset →
peripheral vascular diseaseDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →